S-3 GROUP

Lobbying for ALKERMES, INC. · Global biopharmaceutical company specializing in innovative treatments

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $80,000.00 income · posted Apr 17, 2026

Lobbying activity 1

Alcohol and Drug Abuse

Issues related to legislation and policies that support treatment for alcohol and opioid dependency at SAMSHA, VA and DOJ

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.